Abstract
Objective: To evaluate and compare the effectiveness of tacrolimus 0.1% and triamcinolone acetonide 0.1% used topically to treat symptomatic OLP. Study Design: Cross sectional study. Setting: Oral Medicine Isra Dental College Hyderabad. Period: 1st February 2022 to 31st January 2023. Material & Methods: Total 60 clinically diagnosed patients of symptomatic oral lichen planus were included in study, 60 patients were equally divided into two groups as Group A and group B. Thirty patients of OLP group A were treated with Tracolimus 0.1% four times per day for four weeks and patients of group B were treated with Triamcinolone Acetonide 0.1% ointment. Results: Total 60 symptomatic OLP patients were categorized into to equal groups A and B group. OLP was commonly found in female as compare to male, VAS score and clinical score was calculated before and after the treatment, the mean VAS score of group A was 9.2 (SD±2.07) and group B was 8.9 (SD±2.07) before the treatment. While VAS score of group A 1.9 (SD±1.18) which was treated with tacrolimus (0.1%) and group B score was 2.3 (SD±1.49) which was treated with triamcinolone (0.1%) after the treatment. The mean clinical score of group A was 4.2 (SD±1.14) and 4.6 (SD±1.28) in group B before treatment. Mean clinical score was 1.8 (SD±0.87) in group A and 2.4 (SD±0.9) in group-B after treatment. Conclusion: Study reported Tacrolimus 0.1% is more effective then triamcinolone 0.1% for the treatment of symptomatic OLP however there was no reoccurrence found.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.